SLC1A2 and Huntington disease: Consequently, EAAT2 has emerged as a novel promising therapeutic target for prevention of neuronal excitotoxicity underlying HD and other neurodegenerative diseases (Kim et al., 2011; Limpert and Cosford, 2014; Takahashi et al., 2015).